155 related articles for article (PubMed ID: 19176944)
1. Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors.
Welin S; Stridsberg M; Cunningham J; Granberg D; Skogseid B; Oberg K; Eriksson B; Janson ET
Neuroendocrinology; 2009; 89(3):302-7. PubMed ID: 19176944
[TBL] [Abstract][Full Text] [Related]
2. Correlation of chromogranin A levels and somatostatin receptor scintigraphy findings in the evaluation of metastases in carcinoid tumors.
Namwongprom S; Wong FC; Tateishi U; Kim EE; Boonyaprapa S
Ann Nucl Med; 2008 May; 22(4):237-43. PubMed ID: 18535873
[TBL] [Abstract][Full Text] [Related]
3. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
[TBL] [Abstract][Full Text] [Related]
4. [Gastrointestinal carcinoid tumors: a multi-technique diagnostic approach].
Mathonnet M
J Chir (Paris); 2007; 144(4):287-92. PubMed ID: 17925731
[TBL] [Abstract][Full Text] [Related]
5. Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine Tumors.
Korse CM; Bonfrer JM; Aaronson NK; Hart AA; Taal BG
Neuroendocrinology; 2009; 89(3):296-301. PubMed ID: 18840995
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptor scintigraphy in patients with carcinoid tumors: comparison between radioligand uptake and tumor markers.
Kälkner KM; Janson ET; Nilsson S; Carlsson S; Oberg K; Westlin JE
Cancer Res; 1995 Dec; 55(23 Suppl):5801s-5804s. PubMed ID: 7493349
[TBL] [Abstract][Full Text] [Related]
7. Significance of plasma chromogranin A determination in neuroendocrine tumour (NET) diagnosis.
Donica H; Malecha-Jędraszek A; Strosławska E; Burska A; Szubstarski F
Folia Histochem Cytobiol; 2010 Dec; 48(4):603-10. PubMed ID: 21478104
[TBL] [Abstract][Full Text] [Related]
8. Prognostic clinicopathologic factors in longitudinally followed patients with metastatic small bowel carcinoid tumors.
Curran T; Tulin-Silver S; Patel K; Ward S; Schneiderman M; Harpaz N; Schwartz M; Itzkowitz S; Warner RR; Kim MK
Pancreas; 2011 Nov; 40(8):1253-7. PubMed ID: 21975435
[TBL] [Abstract][Full Text] [Related]
9. Description of patients with midgut carcinoid tumours: clinical database from a Danish centre.
Nykjaer KM; Grønbaek H; Nielsen DT; Christiansen P; Astrup LB
In Vivo; 2007; 21(4):679-84. PubMed ID: 17708366
[TBL] [Abstract][Full Text] [Related]
10. [The diagnostic value of plasma chromogranin A in neuroendocrine tumors].
Yang XO; Li JN; Qian JM; Yang H; Chen Q; Lu L
Zhonghua Nei Ke Za Zhi; 2011 Feb; 50(2):124-7. PubMed ID: 21418832
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers predict outcomes following cytoreductive surgery for hepatic metastases from functional carcinoid tumors.
Jensen EH; Kvols L; McLoughlin JM; Lewis JM; Alvarado MD; Yeatman T; Malafa M; Shibata D
Ann Surg Oncol; 2007 Feb; 14(2):780-5. PubMed ID: 17146740
[TBL] [Abstract][Full Text] [Related]
12. Q RT-PCR detection of chromogranin A: a new standard in the identification of neuroendocrine tumor disease.
Kidd M; Modlin IM; Mane SM; Camp RL; Shapiro MD
Ann Surg; 2006 Feb; 243(2):273-80. PubMed ID: 16432362
[TBL] [Abstract][Full Text] [Related]
13. [Somatostatin receptor scintigraphy in preoperative diagnosis of the site of endocrine gastrointestinal tumors].
Weinel RJ; Kisker O; Joseph K; Welcke U; Zaraca F; Rothmund M
Chirurg; 1994 Oct; 65(10):849-55. PubMed ID: 7821043
[TBL] [Abstract][Full Text] [Related]
14. Increase of urinary 5-hydroxyindoleacetic acid excretion but not serum chromogranin A following over-the-counter 5-hydroxytryptophan intake.
Joy T; Walsh G; Tokmakejian S; Van Uum SH
Can J Gastroenterol; 2008 Jan; 22(1):49-53. PubMed ID: 18209781
[TBL] [Abstract][Full Text] [Related]
15. Gastrointestinal carcinoids: the evolution of diagnostic strategies.
Modlin IM; Latich I; Zikusoka M; Kidd M; Eick G; Chan AK
J Clin Gastroenterol; 2006 Aug; 40(7):572-82. PubMed ID: 16917396
[TBL] [Abstract][Full Text] [Related]
16. Positron emission tomography (PET) in neuroendocrine gastrointestinal tumors.
Eriksson B; Bergström M; Lilja A; Ahlström H; Långström B; Oberg K
Acta Oncol; 1993; 32(2):189-96. PubMed ID: 7686763
[TBL] [Abstract][Full Text] [Related]
17. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution.
Massironi S; Rossi RE; Casazza G; Conte D; Ciafardini C; Galeazzi M; Peracchi M
Neuroendocrinology; 2014; 100(2-3):240-9. PubMed ID: 25428270
[TBL] [Abstract][Full Text] [Related]
18. [Carcinoid tumors].
Pregun I; Bodoky G; Rácz K; Tulassay Z
Orv Hetil; 2010 Nov; 151(46):1885-94. PubMed ID: 21044939
[TBL] [Abstract][Full Text] [Related]
19. Carcinoid syndrome: diagnosis and medical management.
van der Lely AJ; de Herder WW
Arq Bras Endocrinol Metabol; 2005 Oct; 49(5):850-60. PubMed ID: 16444370
[TBL] [Abstract][Full Text] [Related]
20. Chromogranin A predicts survival for resected pancreatic neuroendocrine tumors.
Shanahan MA; Salem A; Fisher A; Cho CS; Leverson G; Winslow ER; Weber SM
J Surg Res; 2016 Mar; 201(1):38-43. PubMed ID: 26850182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
